Amiodarone

• 

  Subject Areas on Research

  • 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 
  • A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. 
  • A novel amiodarone-eluting biological glue for reducing postoperative atrial fibrillation: first animal trial. 
  • A pharmacokinetic model for amiodarone in infants developed from an opportunistic sampling trial and published literature data. 
  • AIM-AF: A Physician Survey in the United States and Europe. 
  • Absence of bilateral vision loss from amiodarone: a randomized trial. 
  • Amiodarone and cyclophosphamide: potential for enhanced lung toxicity. 
  • Amiodarone and reperfusion ventricular fibrillation. 
  • Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. 
  • Amiodarone hepatotoxicity simulating alcoholic liver disease. 
  • Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. 
  • Amiodarone treatment in atrial fibrillation and the risk of incident cancers: A nationwide observational study. 
  • Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality. 
  • Amiodarone use in patients listed for heart transplant is associated with increased 1-year post-transplant mortality. 
  • Amiodarone versus implantable cardioverter defibrillator for asymptomatic nonsustained ventricular tachycardia in nonischemic dilated cardiomyopathy. 
  • Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. 
  • Amiodarone-liposome interaction: a multinuclear NMR and X-ray diffraction study. 
  • An adverse reaction to a medication given to treat an adverse reaction: a teachable moment. 
  • Anesthetic management of an AAI pacemaker patient with paroxysmal atrial fibrillation during colorectal surgery. 
  • Antiarrhythmic agents in older patients. Current state of knowledge. 
  • Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction. 
  • Antiarrhythmic drug use in patients <65 years with atrial fibrillation and without structural heart disease. 
  • Anticoagulation and amiodarone for new atrial fibrillation after coronary artery bypass grafting: Prescription patterns and 30-day outcomes in the United States and Canada. 
  • Aspergillus myocarditis presenting as myocardial infarction with complete heart block. 
  • CASE 6--2012: suspected amiodarone hepatotoxicity after cardiac surgery. 
  • CT of the lung: patterns of calcification and other high-attenuation abnormalities. 
  • Cognitive function and anticoagulation control in patients with atrial fibrillation. 
  • Comparative effectiveness of pharmacotherapies for prevention of atrial fibrillation following coronary artery bypass surgery. 
  • Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. 
  • Comparison of safety of sotalol versus amiodarone in patients with atrial fibrillation and coronary artery disease. 
  • Comparison of survival of amiodarone-treated patients with coronary artery disease and malignant ventricular arrhythmias with that of a control group with coronary artery disease. 
  • Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death. 
  • Cutaneous pigmentation secondary to amiodarone therapy. 
  • Development of a Scoring System to Differentiate Amiodarone-Induced Liver Injury From Alcoholic Steatohepatitis. 
  • Disposition of amiodarone and its proximate metabolite, desethylamiodarone, in the dog for oral administration of single-dose and short-term drug regimens. 
  • Dose-dependent association between amiodarone and severe primary graft dysfunction in orthotopic heart transplantation. 
  • Dronedarone and vitamin K antagonists: a review of drug-drug interactions. 
  • Dronedarone in high-risk permanent atrial fibrillation. 
  • Effect of amiodarone-induced hyperthyroidism on left ventricular outflow obstruction after septal myectomy for hypertrophic cardiomyopathy. 
  • Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator. 
  • Efficacy and tolerance of high-dose intravenous amiodarone for recurrent, refractory ventricular tachycardia. 
  • Ejection fraction assessment and survival: an analysis of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Identification of amiodarone in corneal deposits. 
  • Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. 
  • Interaction between digoxin and dronedarone in the PALLAS trial. 
  • Intravenous amiodarone or magnesium sulphate is not cost-beneficial prophylaxis for atrial fibrillation after coronary artery bypass surgery. 
  • Ion channel inhibition against COVID-19: A novel target for clinical investigation. 
  • Long-Term Outcomes of Implantable Cardioverter-Defibrillator Therapy in the SCD-HeFT. 
  • Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience. Global use of strategies to open occluded coronary arteries. 
  • Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population. 
  • Mixed treatment comparisons for atrial fibrillation: evidence network or bewildering entanglement? 
  • No benefit from defibrillation threshold testing in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). 
  • Outcome in African Americans and other minorities in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Patterns of Care for Atrial Fibrillation Before, During, and at Discharge From Hospitalization: From the Get With The Guidelines-Atrial Fibrillation Registry. 
  • Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. 
  • Pharmacotherapy in Medicare beneficiaries with atrial fibrillation. 
  • Plasma concentration time course and pharmacological effects of a standardized oral amiodarone dosing regimen in humans. 
  • Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. 
  • Prehospital amiodarone may increase the incidence of acute respiratory distress syndrome among patients at risk. 
  • Prevention of atrial fibrillation following cardiac surgery. 
  • Prevention of sudden death in patients with coronary artery disease: the Multicenter Unsustained Tachycardia Trial (MUSTT). 
  • Primary graft dysfunction after heart transplantation: Incidence, trends, and associated risk factors. 
  • Primary prevention with defibrillator therapy in women: results from the Sudden Cardiac Death in Heart Failure Trial. 
  • Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. 
  • Prophylaxis against postoperative atrial fibrillation: current progress and future directions. 
  • Quality of life in patients with implantable cardioverter-defibrillator: systematic review of randomized controlled trials. 
  • Quality of life with defibrillator therapy or amiodarone in heart failure. 
  • Rapid high-performance liquid chromatographic analysis of amiodarone and N-desethyl-amiodarone in serum. 
  • Rate Control versus Rhythm Control for Atrial Fibrillation after Cardiac Surgery. 
  • Real-world implications of QT prolongation in patients receiving voriconazole and amiodarone. 
  • Regional anesthesia for thyroidectomy in two patients with amiodarone-induced hyperthyroidism. 
  • Review: In noncardiac surgery, amiodarone, β-blocker, or statin prophylaxis reduces postoperative AF. 
  • Rhythm control versus rate control for atrial fibrillation and heart failure. 
  • Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Role of amiodarone or implantable cardioverter/defibrillator in patients with atrial fibrillation and heart failure. 
  • SCD-HeFT: Use of R-R interval statistics for long-term risk stratification for arrhythmic sudden cardiac death. 
  • Several new considerations in mitral valve repair. 
  • Syncope predicts the outcome of cardiomyopathy patients: analysis of the SCD-HeFT study. 
  • Thyroid function in heart failure and impact on mortality. 
  • Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias. 
  • Trends Over Time in Drug Administration During Adult In-Hospital Cardiac Arrest. 
  • Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial. 
  • Use of Antiarrhythmic Medications in Medicare Part D Patients With an Implantable Cardioverter-Defibrillator and Ventricular Tachycardia. 
  • Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone: results from the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). 
  • Where patients with mild to moderate heart failure die: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Granger, Christopher Bull, Professor of Medicine, School of Nursing
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology